Dr. Toby Chan team's Retrospective Analysis of Switching Bimatoprost 0.01% to Bimatoprost 0.03% in Patients with Various Types of Glaucoma and Ocular Hypertension.
Reasearch name.
Retrospective Analysis of Switching Bimatoprost 0.01% to Bimatoprost 0.03% in Patients with Various Types of Glaucoma and Ocular Hypertension
Presentation.
Glaucoma is a multifactorial and vision-threatening progressive type of optic neuropathy. Medical therapy with eye drops to reduce intraocular pressure (IOP) remain to be the primary modality of treatment for glaucoma in adults, and adjustment in medication regimen is often required during follow-up to optimize IOP control. In this retrospective study, Dr. Toby Chan’s team has shown that significant reduction in IOP could be achieved after switching from bimatoprost 0.01% to bimatoprost 0.03% in various types of glaucoma.